Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company that regularly issues updates on its cardiac monitoring platform, regulatory milestones, and commercialization plans. Company news highlights its focus on transforming cardiac care through portable, cable-free ECG technologies that can be used by adult patients in clinical settings or at home for arrhythmia assessment.
News releases frequently cover developments related to HeartBeam’s 3D ECG technology and 12-lead ECG synthesis software. These include FDA 510(k) clearance for arrhythmia assessment, the regulatory path for the 12-lead synthesis software, and the company’s responses to a Not Substantially Equivalent (NSE) decision and subsequent successful appeal. Investors can also find updates on clinical studies such as the VALID-ECG study and deep learning research presented at conferences like HRX Live, which examine how HeartBeam’s algorithms perform in detecting atrial fibrillation, atrial flutter, and sinus rhythm.
HeartBeam’s news flow also addresses commercial readiness, including plans for limited U.S. launch with concierge and preventive cardiology practices, establishment of a cardiology reader service, and infrastructure for customer service, contract manufacturing, and logistics. Announcements about the partnership with HeartNexus, Inc. describe how synthesized 12-lead ECGs from HeartBeam’s system will be reviewed by a network of board-certified cardiologists, supporting arrhythmia assessment and patient triage outside traditional healthcare facilities.
In addition, periodic earnings releases and conference participation notices provide insight into the company’s operating expenses, cash position, and engagement with investors and industry partners. Visitors to this news page can review these updates to understand how HeartBeam is progressing on regulatory, clinical, and commercialization objectives for its cardiac monitoring technologies.
HeartBeam, Inc. (NASDAQ: BEAT) reported positive results for its AIMIGo™ 3D VECG system, showcasing progress in clinical and regulatory milestones. The company anticipates FDA clearance by Q2 2024 for the AIMIGo system and plans for a launch by 2024 end. The VALID-ECG pivotal study for the 12-Lead Synthesis Software submission is underway, aiming to demonstrate similarity with a standard 12-lead ECG. HeartBeam AI showed improved performance in detecting arrhythmias, supported by new patents and positive data presented at EHRA conference. Cash and cash equivalents stood at approximately $12.6 million as of March 31, 2024, enabling future clinical and regulatory milestones.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
